Charles River Laboratories International (NYSE:CRL) Director Nancy Andrews Sells 573 Shares

Charles River Laboratories International, Inc. (NYSE:CRL) Director Nancy Andrews sold 573 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $285.24, for a total value of $163,442.52. Following the completion of the transaction, the director owned 1,438 shares in the company, valued at $410,175.12. The trade was a 28.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Charles River Laboratories International Trading Up 1.0%

Shares of NYSE CRL traded up $2.97 during midday trading on Thursday, hitting $292.97. The stock had a trading volume of 1,059,340 shares, compared to its average volume of 927,192. The firm has a market cap of $13.99 billion, a P/E ratio of -60.41, a price-to-earnings-growth ratio of 2.89 and a beta of 1.38. Charles River Laboratories International, Inc. has a fifty-two week low of $144.26 and a fifty-two week high of $299.32. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The company’s 50-day simple moving average is $230.73 and its 200 day simple moving average is $192.57.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.25. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The firm’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Research analysts anticipate that Charles River Laboratories International, Inc. will post 11.35 EPS for the current year.

Institutional Trading of Charles River Laboratories International

A number of institutional investors and hedge funds have recently modified their holdings of CRL. Jones Financial Companies Lllp boosted its stake in Charles River Laboratories International by 167.6% during the 1st quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock worth $253,000 after acquiring an additional 1,074 shares during the last quarter. Empowered Funds LLC bought a new stake in Charles River Laboratories International in the first quarter valued at approximately $418,000. American Century Companies Inc. raised its holdings in Charles River Laboratories International by 41.9% in the second quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock worth $830,000 after purchasing an additional 1,616 shares during the period. Brown Advisory Inc. raised its holdings in Charles River Laboratories International by 5.1% in the second quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock worth $354,000 after purchasing an additional 114 shares during the period. Finally, California Public Employees Retirement System boosted its position in shares of Charles River Laboratories International by 3.9% during the second quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock worth $12,837,000 after purchasing an additional 3,198 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Citigroup reaffirmed a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th. Morgan Stanley boosted their price target on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. BNP Paribas Exane set a $250.00 price objective on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. Weiss Ratings raised shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 1st. Finally, JPMorgan Chase & Co. upgraded shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and upped their target price for the company from $180.00 to $310.00 in a research report on Thursday, August 6th. Twelve investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $255.65.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.